Klaria Pharma Holding Quarterly Report Q1 2019
Klaria Pharma Holding Quarterly Report Q1 2019Encouraging progress in Klaria’s cannabinoid program First three months of the year (January – March) Net sales 3,8 MSEK (0,0 MSEK) R&D costs for the period amounted to 4,8 MSEK (5,1 MSEK) Net income for the period amounted to -2,1 MSEK (-6,2 MSEK) Earnings per share amounted to -0,07 SEK (-0,20 SEK) Cash flow from operations amounted to 0,8 MSEK (-3,7 MSEK) Cash and cash equivalents on the balance day amounted to 8.7 MSEK (13.4 MSEK) Shareholder’s equity per March 31, 2019 amounted to 92.6 MSEK (115.8 MSEK)